Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
暂无分享,去创建一个
S. Patel | P. Hwu | N. Wages | C. Slingluff | W. Olson | G. Petroni | S. Gnjatic | J. Roszik | Elizabeth M. Gaughan | K. Chianese-Bullock | M. Smolkin | N. Varhegyi | Kelly T. Smith | E. Hall | Kathleen Haden